This year, the Golden Helix CancerKB curation team has been hard at work expanding and refining the content that supports cancer variant interpretation and clinical reporting. In addition to staying current with the latest FDA-approved therapies and NCCN Guideline-recommended treatments, the team has taken on a significant new initiative: developing comprehensive diagnostic and prognostic interpretation summaries for the most prominent solid tumors.
This effort builds on last year’s successful curation of diagnostic and prognostic content for hematologic malignancies. Based on valuable feedback from our cancer analysis customers, we recognized a continued need to close the gap in diagnostic and prognostic content, areas frequently cited as the most challenging and time-consuming parts of clinical interpretation.
Addressing Solid Tumor Analysis Challenges
Curating accurate and clinically relevant diagnostic and prognostic information is far from straightforward. Here are a few of the core challenges:
- Trusted cancer resources such as the NCCN Guidelines and the World Health Organization (WHO) classification system both provide authoritative guidance on tumor classification and diagnosis. However, these sources sometimes present differing recommendations or emphasize different criteria. As a result, synthesizing their content into a cohesive, clinically relevant summary for diagnostic decision-making and patient management can be a time-consuming and complex task.
- There is currently no centralized resource that provides structured, machine-readable data readily compatible with bioinformatics pipelines. As a result, generating diagnostic or prognostic interpretation summaries requires time-consuming manual review of clinical guidelines and scientific literature.
- As our understanding of tumor biology deepens through advances in molecular profiling, genomics, and immunohistochemistry, tumor classifications and diagnostic criteria are continually evolving. Clinicians, pathologists, and researchers must stay current with the latest classification systems to ensure optimal patient care and alignment with emerging therapeutic options.
Our Golden Helix CancerKB curation team is tackling these challenges head-on, so you don’t have to. By synthesizing authoritative sources, manually reviewing key literature, and staying on top of evolving classifications, we provide structured, up-to-date diagnostic and prognostic summaries ready to be integrated into your analysis pipeline.
Want to learn more about Golden Helix CancerKB? Contact our team today!
